News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Global Ulcerative Colitis Market: Simponi And Entyvio Launches To Boost Growth By 2022, Says GlobalData

2/13/2014 10:36:35 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LONDON, UK (GlobalData), 13 February 2014 - The global ulcerative colitis (UC) market value will increase steadily over the coming years, growing from almost $4.2 billion in 2012 to approximately $6.6 billion by 2022, at a Compound Annual Growth Rate (CAGR) of 4.7%, according to a new report from research and consulting firm GlobalData.

The company’s latest report* states that out of the 10 major countries (the US, Canada, France, Germany, Italy, Spain, the UK, Japan, China and India), the US will continue to hold the largest UC market share by 2020, with 52%. France and Germany will follow with shares of 11% and 8%, respectively.

Johnson & Johnson (J&J) has been continually dominating the UC market due to the success of Remicade. However, Remicade’s patent is set to expire between 2015 and 2018, which will knock J&J’s sales down from approximately $2 billion in 2012 to $1.5 billion by 2022, according to GlobalData.

Another key player in the UC industry, AbbVie’s Humira, will also lose its patent during the forecast period, with sales slipping from $1.2 billion in 2012 to $569 million by 2022.

However, the UC market will receive a major boost with the entry of J&J’s Simponi and Takeda’s Entyvio, with sales expected to reach an estimated $576 million and $1.3 billion by 2022, respectively.

Eirini Vavatsikou, Ph.D., GlobalData's Analyst covering Immunology, says: “Simponi shows better efficacy in UC than Humira and will therefore allow J&J to retain its positive standing in the UC industry for a longer period of time. On the other hand, Entyvio will have a slow start before gradually reaching blockbuster status, as a result of its remarkably safe profile for a biologic drug.”

Still, a number of barriers will limit any further growth in the UC market, including the lack of curative therapy, diagnostic markers for disease severity, and biologic treatment personalization.

Vavatsikou concludes: “There is also a major need for preventive medicine that lowers the associated risk of colorectal cancer, as well as demand for steroid replacement, oral formulations and the management of infectious adverse events.” *PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022

This report provides an overview of ulcerative colitis (UC), including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current treatment options. It shows annualized UC therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2012 to 2022.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData’s team of industry experts.

For guidelines on how to cite GlobalData, please see:


GlobalData is a leading global research and consulting firm offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.

For more information, please contact our Press Office on +44 (0)1204 543 537 or at

Help employers find you! Check out all the jobs and post your resume.

Read at

comments powered by Disqus